Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Published:2021-04 Issue:4 Volume:19 Page:439-457
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Tempero Margaret A.¹,Malafa Mokenge P.²,Al-Hawary Mahmoud³,Behrman Stephen W.⁴,Benson Al B.⁵,Cardin Dana B.⁶,Chiorean E. Gabriela⁷,Chung Vincent⁸,Czito Brian⁹,Del Chiaro Marco¹⁰,Dillhoff Mary¹¹,Donahue Timothy R.¹²,Dotan Efrat¹³,Ferrone Cristina R.¹⁴,Fountzilas Christos¹⁵,Hardacre Jeffrey¹⁶,Hawkins William G.¹⁷,Klute Kelsey¹⁸,Ko Andrew H.¹,Kunstman John W.¹⁹,LoConte Noelle²⁰,Lowy Andrew M.²¹,Moravek Cassadie²²,Nakakura Eric K.¹,Narang Amol K.²³,Obando Jorge⁹,Polanco Patricio M.²⁴,Reddy Sushanth²⁵,Reyngold Marsha²⁶,Scaife Courtney²⁷,Shen Jeanne²⁸,Vollmer Charles²⁹,Wolff Robert A.³⁰,Wolpin Brian M.³¹,Lynn Beth³²,George Giby V.³²

Affiliation:

1. 1UCSF Helen Diller Family Comprehensive Cancer Center;

2. 2Moffitt Cancer Center;

3. 3University of Michigan Rogel Cancer Center;

4. 4The University of Tennessee Health Science Center;

5. 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

6. 6Vanderbilt-Ingram Cancer Center;

7. 7Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

8. 8City of Hope National Medical Center;

9. 9Duke Cancer Institute;

10. 10University of Colorado Cancer Center;

11. 11The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

12. 12UCLA Jonsson Comprehensive Cancer Center;

13. 13Fox Chase Cancer Center;

14. 14Massachusetts General Hospital Cancer Center;

15. 15Roswell Park Comprehensive Cancer Center;

16. 16Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

17. 17Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

18. 18Fred & Pamela Buffett Cancer Center;

19. 19Yale Cancer Center/Smilow Cancer Hospital;

20. 20University of Wisconsin Carbone Cancer Center;

21. 21UC San Diego Moores Cancer Center;

22. 22Pancreatic Cancer Action Network;

23. 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

24. 24UT Southwestern Simmons Comprehensive Cancer Center;

25. 25O’Neal Comprehensive Cancer Center at UAB;

26. 26Memorial Sloan Kettering Cancer Center;

27. 27Huntsman Cancer Institute at the University of Utah;

28. 28Stanford Cancer Institute;

29. 29Abramson Cancer Center at the University of Pennsylvania;

30. 30The University of Texas MD Anderson Cancer Center;

31. 31Dana-Farber/Brigham and Women’s Cancer Center;

32. 32National Comprehensive Cancer Network.

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients’ advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/19/4/article-p439.xml

Cited by 673 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance;Drug Resistance Updates;2024-11

2. The Role of Bile Acids in Pancreatic Cancer;Current Cancer Drug Targets;2024-10

3. Validation of a targeted next-generation sequencing panel for pancreatic ductal adenocarcinomas;Experimental and Molecular Pathology;2024-10

4. Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma;Surgical Clinics of North America;2024-10

5. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic cancer;Surgery;2024-10